Eli Lilly and Co. (LLY: Quote) announced that dulaglutide, its investigational, long-acting glucagon-like peptide 1, or GLP-1, analog being studied as a once-weekly treatment for type 2 diabetes, met its primary endpoint of non-inferiority for mean 24-hour systolic blood pressure after 16 weeks.
According to the company, the results came from a Phase II study that compared two doses of dulaglutide to placebo, using ambulatory blood pressure monitoring to characterize changes in blood pressure and heart rate. Also, the 1.5 mg dulaglutide dose significantly reduced mean 24-hour SBP compared to placebo.
Gwen Krivi, vice president, product development, Lilly Diabetes, said, "We are very encouraged by these clinical trial results, in addition to the rest of the clinical trial data we've seen to date for dulaglutide. Dulaglutide is currently in Phase III clinical trials, where it will continue to be evaluated on its efficacy to lower blood glucose levels, overall safety, weight effects and effects on cardiovascular outcomes. We believe dulaglutide, if approved, can bring significant benefits to people with type 2 diabetes."
Click here to receive FREE breaking news email alerts for Eli Lilly And Co. and others in your portfolio
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News